Skip to content
Screener

Exelixis EXEL Contract Liabilities

Contract Liabilities at other companies

Kura Oncology logo
Kura OncologyKURA
$416.75M+53.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$56M-57.3%
Gilead Sciences logo
Gilead SciencesGILD
$50M-13.8%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$13.4B+33.0%
Enterprise value$13.28B+31.7%
P/E15.6×-1.2×
P/S5.5×+1.0×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemJune 30, 2026December 31, 2025
Contract liabilities:
Current portion(1)$1,032$1,115
Non-current portion(2)4,6676,112
Total contract liabilities$5,699$7,227

Item 1. Financial Statements.

FAQ

What is Exelixis's contract liabilities?
Exelixis (EXEL) reported contract liabilities of $4.67M in Q2 2026.
How has Exelixis's contract liabilities changed year-over-year?
Exelixis's contract liabilities increased by 78.1% year-over-year, from $2.62M to $4.67M.
What is the long-term trend for Exelixis's contract liabilities?
Over 5 years (2020 to 2025), Exelixis's contract liabilities has grown at a 10.2% compound annual growth rate (CAGR), from $3.76M to $6.11M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Ask your AI about Exelixis's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude